Differentially expressed KEGG pathways between high- and low-risk patients included cancer cell signaling pathways (MAPK, VEGF, MTOR, and ERBB signaling pathways) and cancer pathways (acute myeloid leukemia, non-small cell lung cancer, chronic myeloid leukemia, and pancreatic cancer; Table 3). This evidence concerns the gene EGFR and acute myeloid leukemia.